Excerpt from the GMP Compliance Adviser Chapter 14.N Elemental impurities
The heavy metals test is no longer included in pharmacopeias.
A scientifically-based risk assessment is required for the evaluation of elemental impurities.
It is possible to perform the implementation of ICH Q3D by two well differentiated approaches:
This approach has advantages from a science and transparency point of view and it is the option encouraged by the EMA (if suitable). In this approach, the contribution of elemental impurities from each component is identified and analyzed. Then, the combined contribution of an element is compared with the PDE in the risk assessment.
In practice, the component approach consists in gathering data from all the components, covering data gaps by analyses of components (or literature, databases, prior knowledge...), and summarizing the concentration of elemental impurities in all the components of a given drug product. Then, evaluation options 1, 2a and 2b are used for the evaluation step and the comparison against the control threshold will provide the results of the risk assessment.
This approach consists in the experimental analysis of batches of the drug product for the presence of any elemental impurities. The results would support the risk assessment to justify a control strategy. Where necessary, the control strategy will include specification(s) for the drug product. Analytical data, without a risk assessment, will not be sufficient to omit a specification for an element. With a risk assessment, depending on its outcome, the number of batches analysed should be commensurate with the risk of the elemental impurities present.
In practice, the product approach requires a risk assessment that determines the elemental impurities to be analysed, the number of batches to be analyzed, and the limits of detection required for each element. With these results, the evaluation is performed according to option 3, and the comparison with the control threshold will provide the results of the risk assessment.
The flowchart shown in Figure 14.N-9 summarizes the different approaches for the implementation.
Figure 14.N-9 Summary of the implementation approaches of ICH Q3D
The selection of the approach is a critical decision for the implementation of ICH Q3D. This section discusses the pros and cons of each approach, which may be considered for decision-taking. The facts are summarized in Figure 14.N-10.
|Pros and cons of Component and Product Approaches|
Figure 14.N-10 Pros and cons of the different approaches for ICH Q3D implementation
Author’s note: From a practical point of view, the component approach is always encouraged. It takes more effort but provides very good results, so it is profitable. However, the drug product approach might be a better option in certain cases:
Regardless of the selected approach, good planning is the key to achieve a successful implementation of ICH Q3D: potentially the two approaches may be combined (e.g. the risk associated to a given manufacturing line can be addressed through experimental analysis of the 'worst-case' product in that line). In this planning, it is highly recommended to be very systematic in data gathering. It should be good practice that the suppliers are considered as partners.
Irrespective of the approach, there is documentation to be generated in order to comply with the regulatory requirements of ICH Q3D. This section describes briefly how to manage the various documents:
Internal documentation: The complete risk assessment documentation should be kept in-site available for inspection. Authorities may also ask for
Regulatory file documentation: The dossier should include a summary of the risk assessment including a brief description of
Paulino Alonso, PhD
Medinsa, Laboratorios Medicamentos Internacionales, S.A., Madrid
Save time and ressources:
Let us prepare your regulatory toxicological assessments: